US2016136135A1PendingUtilityA1

Method of treatment of cns disorders

52
Assignee: SUPERNUS PHARMACEUTICALS INCPriority: Dec 2, 2009Filed: Jul 10, 2015Published: May 19, 2016
Est. expiryDec 2, 2029(~3.4 yrs left)· nominal 20-yr term from priority
Inventors:Christopher Breder
A61P 25/22A61P 25/24A61P 25/00A61P 25/28A61K 31/00A61K 31/4188A61K 9/0053
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity.

Claims

exact text as granted — not AI-modified
1 .- 9 . (canceled) 
     
     
         10 . A method of treating attention deficit hyperactivity disorder in a mammalian subject comprising administering to a subject in need thereof a total dose of 0.1 mg to 0.5 mg of mazindol per day as the sole active agent. 
     
     
         11 . The method of  claim 10 , wherein the mammalian subject is orally administered mazindol.

Join the waitlist — get patent alerts

Track US2016136135A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.